Sunmax Biotechnology Co., Ltd. (TPEX:4728)
Taiwan · Delayed Price · Currency is TWD 389.50
-1.50 (-0.38%)
At close: Feb 11, 2026
Sunmax Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 716.94 | 679.41 | 625.71 | 533.83 | 245.64 | 238.08 |
Depreciation & Amortization | 100.92 | 99.21 | 72.83 | 58.15 | 55.76 | 33.8 |
Loss (Gain) From Sale of Assets | 0.78 | 0.49 | 0.13 | -0.46 | 2.1 | -1.34 |
Loss (Gain) From Sale of Investments | - | - | - | - | - | 8.32 |
Provision & Write-off of Bad Debts | - | - | - | -0.39 | 0.24 | -2.38 |
Other Operating Activities | 4.57 | -21.59 | 17.96 | 42.52 | 18.34 | -1.97 |
Change in Accounts Receivable | 0.11 | 0.47 | -0.23 | 3.34 | 1.81 | 12.81 |
Change in Inventory | -16.91 | -63.69 | -19.88 | -19.05 | -29.41 | 6.1 |
Change in Accounts Payable | -5.88 | 11.35 | -7.61 | 9.46 | 3.58 | -3.34 |
Change in Unearned Revenue | -23.86 | -128.72 | 142.48 | -62.86 | 11.01 | 50.81 |
Change in Other Net Operating Assets | 29.18 | -15.91 | 17.17 | 80.03 | -65.8 | 46.09 |
Operating Cash Flow | 805.84 | 561.04 | 848.56 | 644.57 | 243.28 | 386.97 |
Operating Cash Flow Growth | 46.47% | -33.88% | 31.65% | 164.95% | -37.13% | 33.67% |
Capital Expenditures | -25.94 | -31.97 | -107.66 | -154.58 | -253.02 | -129.87 |
Sale of Property, Plant & Equipment | - | - | 0.42 | 0.51 | 3.1 | 0.61 |
Cash Acquisitions | -7.2 | -7.2 | - | - | - | - |
Sale (Purchase) of Intangibles | -9.42 | -5.03 | -2.73 | -0.59 | -2.4 | -0.23 |
Sale (Purchase) of Real Estate | - | - | -0.96 | - | - | - |
Investment in Securities | -151 | 24.96 | 125 | -136.43 | 39.68 | 28.88 |
Other Investing Activities | -7.86 | -2.71 | -30.1 | -85.53 | -72.53 | -1.29 |
Investing Cash Flow | -201.41 | -21.94 | -16.04 | -376.62 | -285.17 | -101.9 |
Long-Term Debt Repaid | - | -29.65 | -22.97 | -39.16 | -24.39 | -14.81 |
Net Debt Issued (Repaid) | -29.84 | -29.65 | -22.97 | -39.16 | -24.39 | -14.81 |
Common Dividends Paid | -631.77 | -599.09 | -517.4 | -239.64 | -108.93 | -81.7 |
Other Financing Activities | -0.33 | 2.64 | -9.43 | -2.41 | 1.35 | 1.13 |
Financing Cash Flow | -661.94 | -626.11 | -549.8 | -281.21 | -131.97 | -95.38 |
Foreign Exchange Rate Adjustments | -9.9 | 7.79 | -17.33 | 0.01 | -2.18 | 5.39 |
Net Cash Flow | -67.41 | -79.23 | 265.39 | -13.25 | -176.03 | 195.09 |
Free Cash Flow | 779.91 | 529.07 | 740.9 | 489.99 | -9.74 | 257.11 |
Free Cash Flow Growth | 63.72% | -28.59% | 51.21% | - | - | -6.79% |
Free Cash Flow Margin | 39.05% | 29.10% | 43.87% | 35.00% | -0.94% | 30.04% |
Free Cash Flow Per Share | 14.30 | 9.70 | 13.59 | 8.98 | -0.18 | 4.71 |
Cash Interest Paid | 5 | 5.95 | 2.94 | 1.35 | 2.81 | 2.92 |
Cash Income Tax Paid | 286.75 | 289.64 | 259.68 | 199.74 | 92.59 | 100.69 |
Levered Free Cash Flow | 672.64 | 400.4 | 612.07 | 412.52 | 7.73 | 152.81 |
Unlevered Free Cash Flow | 675.77 | 404.12 | 613.91 | 413.36 | 9.48 | 154.63 |
Change in Working Capital | -17.37 | -196.49 | 131.93 | 10.91 | -78.8 | 112.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.